The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence

CNS Drugs

Volumn 26, Issue 8, 2012, Pages 663-690

  Sani, Gabriele ^a,b   Serra, Giulia ^a   Kotzalidis, Giorgio D ^a   Romano, Silvia ^a   Tamorri, Stefano M ^a   Manfredi, Giovanni ^a   Caloro, Matteo ^a   Telesforo, C Ludovica ^a   Caltagirone, Saverio S ^a   Panaccione, Isabella ^a   Simonetti, Alessio ^a,b   Demontis, Francesca ^c   Serra, Gino ^c   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Centro Lucio Bini   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Anxiety disorders; Attention deficit hyperactivity disorder; Bipolar disorders; Catatonia; Dementia; Eating disorders; Gambling; Impulse control disorders; Major depressive disorder; Memantine; NMDA receptor antagonists; Schizophrenia; Substance related disorders.

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; DESIPRAMINE; DIZOCILPINE; DONEPEZIL; ESCITALOPRAM; GALANTAMINE; GLUTAMIC ACID; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MEMANTINE; RIVASTIGMINE; VALPROIC ACID;

ALCOHOLISM; ANOREXIA NERVOSA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BULIMIA; CATATONIA; COCAINE DEPENDENCE; CONSTIPATION; DEMENTIA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EATING DISORDER; EXCITOTOXICITY; FATIGUE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERTENSION; INFERIOR FRONTAL GYRUS; INFERIOR PARIETAL LOBULE; MAJOR DEPRESSION; MEDLINE; MENTAL DISEASE; NAUSEA; NERVE CELL PLASTICITY; NIGHT SWEAT; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PARANOID SCHIZOPHRENIA; PATHOLOGICAL GAMBLING; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; SUBSTANCE ABUSE; TREATMENT DURATION; WORKING MEMORY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; MENTAL DISORDERS; TREATMENT OUTCOME;

EID: 84863685351     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11634390-000000000-00000     Document Type: Review

References (238)

1. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol 2008; 6: 55-78
2. Monaghan DT, Jane DE. Pharmacology of NMDA receptors. In: Van Dongen AM, editor. Biology of the NMDA receptor (frontiers in neuroscience). Boca Raton (FL): CRC Press, 2009: 257-82
3. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 2008; 62: 149-53
4. Kornhuber J, Bormann J, Retz W, et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortemhuman frontal cortex. Eur J Pharmacol 1989; 166: 589-90
5. La Spada AR. Memantine strikes the perfect balance. Nat Med 2009; 15: 1355-6
6. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 38: 735-67
7. Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2010; 25: 547-53
8. Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf 2008; 31: 577-85
9. Dolder C, Nelson M, McKinsey J. Memantine dosing in patients with dementia. Am J Geriatr Psychiatry 2009; 17: 170-3
10. Dubey SK, Patni A, Khuroo A, et al. A quantitative analysis of memantine in human plasma using ultra performance liquid chromatography/tandem mass spectrometry. E-J Chem 2009; 6: 1063-70
11. Liu MY, Meng SN, Wu HZ, et al. Pharmacokinetics of single-dose and multiple-dose memantine in healthy Chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clin Ther 2008; 30: 641-53
12. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007; 46: 599-612
13. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79: 134-43
14. Wesemann W, Sontag KH, Maj J. Zur Pharmakodynamik und Pharmakokinetic des Memantin. Arzneimittelforschung 1983; 33: 1122-34
15. Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38: 1389-94
16. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519-28
17. Shua-Haim J, Smith J, Picard F, et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by coadministration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig 2008; 28: 361-74
18. Berk M, Dodd S, Kauer-Sant'anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand 2007; 116 Suppl. 434: 41-9
19. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11: 787-806
20. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992; 33: 115-20
21. Serra G, Argiolas A, Klimek V, et al. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci 1979; 25: 415-23
22. Serra G, Collu M, D'Aquila PS, et al. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol Toxicol 1992; 71 Suppl. 1: 72-85
23. Braestrup C, Andersen H, Randrup A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 1975; 34: 181-7
24. Randrup A, Munkvad J, Fog R. Mania, depression and brain dopamine. In: Essman WB, Valzelli L, editors. Current developments in psychopharmacology. New York (NY): Spectrum, 1975: 206-48
25. Molander L, Randrup A. Effects of thymoleptics on behavior associated with changes in brain dopamine: II. Modification and potentiation of apomorphine-induced stimulation of mice. Psychopharmacology (Berl) 1976; 49: 139-44
26. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 1977; 53: 309-14
27. Serra G, Argiolas A, Fadda F, et al. Hyposensitivity of dopamine "autoreceptors" induced by chronic administration of tricyclic antidepressants. Pharmacol Res Commun 1980; 12: 619-24
28. Spyraki C, Fibiger HC. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 1981; 74: 195-206
29. Serra G, Collu M, D'Aquila PS, et al. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Res 1990; 527: 234-43
30. Gessa GL, Pani L, Serra G, et al. Animal models of mania. In: Fratta W, Pani L, Gessa GL, et al., editors. Depression and mania: from neurobiology to treatment. New York (NY): Raven Press, 1995: 43-66
31. Collu M, Poggiu AS, Devoto P, et al. Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. Eur J Pharmacol 1997; 322: 123-7
32. Collu M, D'Aquila P, Gessa GL, et al. Do antidepressant treatments induce mania by activating dopaminergic transmission? Second international conference on bipolar disorders; 1997 Jun 19-21; Pittsburgh (PA)
33. D'Aquila PS, Collu M, Gessa GL, et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365-73
34. Serra G, D'Aquila PS. Do antidepressants induce mania and rapid cycling by increasing dopaminergic transmission? TDM 2008 International Meeting; 2008 Oct 2-3; Bologna: 54-55
35. Serra G. Memantine for treating bipolar mood disorders resistant to conventional treatments. EP patent 2 218 450 A1. 2010 Aug 18
36. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980; 13: 156-67
37. D'Aquila PS, Peana AT, Panin F, et al. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur J Pharmacol 2003; 458: 129-34
38. D'Aquila PS, Panin F, Serra G. Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur J Pharmacol 2004; 492: 61-3
39. Koukopoulos A, Ghaemi SN. The primacy of mania: a reconsideration of mood disorders. Eur Psychiatry 2009; 24: 125-34
40. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-9
41. Tondo L, Laddomada P, Serra G, et al. Rapid cyclers and antidepressants. Int Pharmacopsychiat 1981; 16: 119-23
42. Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive metaanalytic review. Acta Psychiatr Scand 2010; 121: 404-14
43. D'Aquila PS, Collu M, Devoto P, et al. Chronic lithium chloride fails to prevent imipramine-induced sensitization to the dopamine-D2-like receptor agonist quinpirole. Eur J Pharmacol 2000; 395: 157-60
44. D'Aquila PS, Peana AT, Tanda O, et al. Carbamazepine prevents imipramine-induced behavioural sensitization to the D2-like dopamine receptor agonist quinpirole. Eur J Pharmacol 2001; 416: 107-11
45. D'Aquila PS, Panin F, Serra G. Chronic valproate fails to prevent imipramine-induced behavioural sensitization to the dopamine D2-like receptor agonist quinpirole. Eur J Pharmacol 2006; 535: 208-11
46. Nakagawa T, Suzuki Y, Nagayasu K, et al. Repeated exposure to methamphetamine, cocaine or morphine induces augmentation of dopamine release in rat mesocorticolimbic slice co-cultures. PLoS One 2011; 6: e24865
47. Prieto-Gomez B, Benitez MT, Vazquez-Alvarez AM, et al. Dopaminergic ventral tegmental neurons modulated by methylphenidate. Life Sci 2004; 74: 1581-92
48. Acerbo MJ, Lee JM, Delius JD. Sensitization to apomorphine, effects of dizocilpine NMDA receptor blockades. Behav Brain Res 2004; 151: 201-8
49. Broadbent J, Kampmueller KM, Koonse SA. Expression of behavioral sensitization to ethanol by DBA/2J mice: the role of NMDA and non-NMDA glutamate receptors. Psychopharmacology (Berl) 2003; 167: 225-34
50. Pacchioni AM, Gioino G, Assis A, et al. A single exposure to restraint stress induces behavioral and neurochemical sensitization to stimulating effects of amphetamine: involvement of NMDA receptors. Ann N Y Acad Sci 2002; 965: 233-46
51. D'Aquila PS, Sias A, Gessa GL, et al. The NMDA receptor antagonist MK-801 prevents imipramine-induced supersensitivity to quinpirole. Eur J Pharmacol 1992; 224: 199-202
52. D'Aquila PS, Collu M, Gessa GL, et al. Dizolcipine prevents the enhanced locomotor response to quinpirole induced by repeated electroconvulsive shock. Eur J Pharmacol 1997; 330: 11-4
53. Koukopoulos A, Reginaldi D, Serra G, et al. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 2010; 12: 348-9
54. Meloni D, Gambarana C, De Montis MG, et al. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 1993; 46: 423-6
55. De Montis MG, Gambarana C, Meloni D, et al. Long-term imipramine effects are prevented by NMDA receptor blockade. Brain Res 1993; 606: 63-7
56. Malesa R, Serra G. La memantina previene la sensibilizzazione dei recettori dopaminergici indotta dall'imipramina [dissertation]. Sassari: School of Pharmacy, University of Sassari, 2011
57. Demontis F, Serra G. Effetto stabilizzante dell'umore della Memantina: evidenze sperimentali [dissertation]. Sassari: School of Pharmacy, University of Sassari, 2011
58. Cubeddu A, Serra G. La memantina previene la "depressione" da interruzione del trattamento con imipramine [dissertation]. Sassari: School of Pharmacy, University of Sassari, 2011
59. Ongur D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interaction in acute mania. Biol Psychiatry 2008; 64: 718-26
60. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5: 11-25
61. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 2003; 100: 1387-92
62. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. AmJ Psychiatry 2004; 161: 1957-66
63. Gao Y, Payne RS, Schurr A, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res 2011; 188: 366-71
64. Keck Jr PE, Hsu HA, Papadakis K, et al. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 2009; 32: 199-204
65. Koukopoulos A, Serra G, Koukopoulos AE, et al. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 2012; 136: 163-6
66. Serra G. A naturalistic study on antimanic and mood stabilizing effect of memantine in treatment-resistant bipolar disorders. International Review of Bipolar Disorders; 2011 Apr 4-6; Rome
67. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-71
68. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010; 22: 346-72
69. Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a doubleblind, randomized, placebo-controlled trial. Bipolar Disord 2012; 14: 64-70
70. Kim JS, Schmid-Burgk W, Claus D, et al. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982; 232: 299-304
71. Levine J, Panchalingam K, Rapoport A, et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000; 47: 586-93
72. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtypespecific alterations of g-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705-13
73. Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004; 372: 173-7
74. Beneyto M, Kristiansen LV, Oni-Orisan A, et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007; 32: 1888-902
75. Maeng S, Zarate Jr CA. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007; 9: 467-74
76. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011; 224: 107-11
77. Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64
78. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67: 139-45
79. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 522-6
80. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011; 14: 1127-31
81. Res GZ, Stringari RB, Kirsch TR, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull 2010; 81: 585-9
82. Castre E, Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010; 70: 289-97
83. Loi F, Serra G. Effetto antidepressivo-simile della memantina nel FST: un falso positive [dissertation]. Sassari: School of Pharmacy, University of Sassari, 2011
84. Quan MN, Zhang N, Wang YY, et al. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience 2011; 182: 88-97
85. Feyissa AM, Chandran A, Stockmeier CA, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 70-5
86. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007; 30: 136-44
87. Zarate Jr CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-5
88. Muhonen LH, Lonnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008; 69: 392-9
89. Muhonen LH, Lahti J, Sinclair D, et al. Treatment of alcohol dependence in patients with co-morbid major depressive disorder: predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy 2008; 3: 20
90. Munoz C, Yulan N, Achaval V, et al. Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008; 20: 119-20
91. Kollmar R, Markovic K, Thurauf N, et al. Ketamine followed by memantine for the treatment of major depression [letter]. Aust N Z J Psychiatry 2008; 42: 170
92. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat 2002; 8: 189-97
93. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci 2003; 1003: 119-30
94. Kim JS, Kornhuber HH, Schmid-Burgk W, et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-82
95. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214
96. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8
97. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006; 11: 118-9
98. Gilmour G, Pioli EY, Dix SL, et al. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl) 2009; 205: 203-16
99. Dingledine R, Borges K, Bowie D, et al. The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61
100. Hill SK, Ragland JD, Gur RC, et al. Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes. J Clin Exp Neuropsychol 2002; 24: 765-80
101. Hill SK, Beers SR, Kmiec JA, et al. Impairment of verbal memory and learning in antipsychotic-naive patients with first-episode schizophrenia. Schizophr Res 2004; 68: 127-36
102. Hill SK, Schuepbach D, Herbener ES, et al. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr Res 2004; 68: 49-63
103. Hill SK, Harris MS, Herbener ES, et al. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr Bull 2008; 34: 743-59
104. Smith JW, Gastambide F, Gilmour G, et al. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl) 2011; 217: 255-69
105. Young JW, Powell SB, Risbrough V, et al. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009; 122: 150-202
106. Dunnett SB. Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology (Berl) 1985; 87: 357-63
107. Barch DM, Berman MG, Engle R, et al. CNTRICS final task selection: working memory. Schizophr Bull 2009; 35: 136-52
108. Barch DM, Carter CS, Arnsten A, et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 2009; 35: 109-14
109. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006; 6: 61-7
110. Braff D, Stone C, Callaway E, et al. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978; 15: 339-43
111. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001; 156: 234-58
112. Ison JR, Hammond GR. Modification of the startle reflex in the rat by changes in the auditory and visual environments. J Comp Physiol Psychol 1971; 75: 435-52
113. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 1989; 2: 299-308
114. Mansbach RS. Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur J Pharmacol 1991; 202: 61-6
115. Mansbach RS, Geyer MA. Parametric determinants in prestimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl) 1991; 105: 162-8
116. Martinez ZA, Ellison GD, Geyer MA, et al. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 1999; 21: 28-39
117. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 1993; 14: 325-31
118. Danysz W, Zajaczkowski W, Parsons CG. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol 1995; 6: 455-74
119. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents: toward an understanding of their favorable tolerability. Amino Acids 2000; 19: 133-49
120. Wiley JL, Harvey SA, Balster RL, et al. Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. Psychopharmacology (Berl) 2003; 165: 378-85
121. Swerdlow NR, van Bergeijk DP, Bergsma F, et al. The effects of memantine on prepulse inhibition. Neuropsychopharmacology 2009; 34: 1854-64
122. Petrovic M, Hora M, Sedlacek M, et al. Physiology and pathology of NMDA receptors. Prague Med Rep 2005; 106: 113-36
123. Duncan GE, Leipzig JN, Mailman RB, et al. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998; 812: 65-75
124. Dedeurwaerdere S, Wintmolders C, Straetemans R, et al. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology (Berl) 2011; 214: 505-14
125. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916
126. Seki T, Arai Y. Highly polysialylated neural cell adhesion molecule (NCAM-H) is expressed by newly generated granule cells in the dentate gyrus of the adult rat. J Neurosci 1993; 13: 2351-8
127. Seki T, Arai Y. Age-related production of new granule cells in the adult dentate gyrus. Neuroreport 1995; 6: 2479-82
128. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005; 28: 223-50
129. Namba T, Ming GL, Song H, et al. NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via Disrupted-In-Schizophrenia 1 (DISC1). J Neurochem 2011; 118: 34-44
130. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 984-97, 979
131. Tsai GE, Lin PY. Strategies to enhance N-methyl-Daspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010; 16: 522-37
132. Berger GE, Wood S, McGorry PD. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol Bull 2003; 37: 79-101
133. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
134. Verma A, Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 1996; 16: 373-9
135. Lisman JE, Fellous JM, Wang XJ. A role for NMDAreceptor channels in working memory. Nat Neurosci 1998; 1: 273-5
136. Thomas C, Carroll BT, Maley RT, et al. Memantine and catatonic schizophrenia [letter]. Am J Psychiatry 2005; 162: 626
137. Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40: 344-6
138. Carroll BT, Thomas C, Jayanti K. Amantadine and memantine in catatonic schizophrenia. Ann Clin Psychiatry 2006; 18: 133-4
139. Ponde MP, Novaes CM. Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia [letter]. Rev Bras Psiquiatr 2007; 29: 92
140. Cerullo MA, Adler CM, Strakowski SM, et al. Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study. Schizophr Res 2007; 97: 294-6
141. Krivoy A, Weizman A, Laor L, et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol 2008; 18: 117-21
142. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 3: 1322-9
143. de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416-23. Erratum in: J Clin Psychiatry 2011; 72: 1157
144. de Lucena D, Fernandes BS, Kunz M, et al. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine. J Clin Psychiatry 2010; 71: 91-2
145. Xiu MH, Hui L, Dang YF, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on longterm treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1508-12
146. Gray L, van den Buuse M, Scarr E, et al. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 2009; 12: 45-60
147. Fornaro M. Catatonia: a narrative review. Cent Nerv Syst Agents Med Chem 2011; 11: 73-9
148. Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007; 19: 406-12
149. Obregon DF, Velasco RM, Wuerz TP, et al. Memantine and catatonia: a case report and literature review. J Psychiatr Pract 2011; 17: 292-9
150. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology Bull 2009; 42: 81-93
151. Wu K, Hanna GL, Rosenberg DR, et al. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012; 100: 726-35
152. Egashira N, Okuno R, Harada S, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008; 586: 164-70
153. Wald R, Dodman N, Shuster L. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder. Exp Clin Psychopharmacol 2009; 17: 191-7
154. Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry 2005; 162: 2191-2
155. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1173-5
156. Hezel DM, Beattie K, Stewart SE. Memantine as an augmenting agent for severe pediatric OCD [letter]. Am J Psychiatry 2009; 166: 237
157. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009; 29: 51-5
158. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessivecompulsive disorder. J Clin Psychopharmacol 2010; 30: 34-9
159. Adamec R. Transmitter systems involved in neural plasticity underlying increased anxiety and defense: implications for understanding anxiety following traumatic stress. Neurosci Biobehav Rev 1997; 21: 755-65
160. Harvey BH, Bothma T, Nel A, et al. Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor Kbeta in an animal model of repeated trauma. Hum Psychopharmacol 2005; 20: 367-73
161. Battista MA, Hierholzer R, Khouzam HR, et al. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry 2007; 70: 167-74
162. Chopra MP, Trevino KM, Kowall NW. Memantine for posttraumatic stress disorder in an older veteran. J Clin Psychopharmacol 2011; 31: 787-8
163. Dannon PN, Lowengrub K, Gonopolski Y, et al. Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Prim Care Companion J Clin Psychiatry 2006; 8: 334-9
164. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000
165. Potenza MN. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3181-9
166. Goudriaan AE, de Ruiter MB, van den Brink W, et al. Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study. Addict Biol 2010; 15: 491-503
167. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008; 75: 63-75
168. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8: 147-8
169. Nussbaum D, Honarmand K, Govoni R, et al. An eight component decision-making model for problem gambling: a systems approach to stimulate integrative research. J Gambl Stud 2011; 27: 523-63
170. Olive MF, Cleva RM, Kalivas PW, et al. Glutamatergic medications for the treatment of drug and behavioural addictions. Pharmacol Biochem Behav 2012; 100: 801-10
171. Winstanley CA. The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol 2011; 164: 1301-21
172. Nordin C, Gupta RC, Sjodin I. Cerebrospinal fluid amino acids in pathological gamblers and healthy controls. Neuropsychobiology 2007; 56: 152-8
173. Meroni MC, Lo Giudice A, Kotzalidis GD, et al. Improvement of pathologic gambling symptoms after administration of sertraline: a case report. J Clin Psychopharmacol 2004; 24: 350-1
174. Roncero C, Rodruez-Urrutia A, Grau-Lopez L, et al. Trastornos del control de impulsos y tratamiento con antiepileticos. Actas Esp Psiquiatr 2009; 37: 205-12
175. Grant JE, Odlaug BL, Potenza MN, et al. Nalmefene in the treatment of pathological gambling: multicentre, doubleblind, placebo-controlled study. Br J Psychiatry 2010; 197: 330-1. Erratum in: Br J Psychiatry 2011; 198: 75
176. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62: 652-7
177. Saiz-Ruiz J, Blanco C, Iba?̃ez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005; 66: 28-33
178. Stanley BG, Urstadt KR, Charles JR, et al. Glutamate and GABA in lateral hypothalamic mechanisms controlling food intake. Physiol Behav 2011; 104: 40-6
179. Reddy DS, Kulkarni SK. The role of GABA-A and mitochondrial diazepam-binding inhibitor receptors on the effects of neurosteroids on food intake in mice. Psychopharmacology (Berl) 1998; 137: 391-400
180. Tsuda M, Suzuki T, Misawa M. NMDA receptor antagonists potently suppress the spontaneous withdrawal signs induced by discontinuation of long-term diazepam treatment in Fischer 344 rats. Brain Res 1998; 790: 82-90
181. Blevins JE, Truong BG, Gietzen DW. NMDA receptor function within the anterior piriform cortex and lateral hypothalamus in rats on the control of intake of amino acid-deficient diets. Brain Res 2004; 1019: 124-33
182. Popik P, Kos T, Zhang Y, et al. Memantine reduces consumption of highly palatable food in a rat model of binge eating. Amino Acids 2011; 40: 477-85
183. Bisaga A, Danysz W, Foltin RW. Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. Eur Neuropsychopharmacol 2008; 18: 794-802
184. Koronyo-Hamaoui M, Frisch A, Stein D, et al. Dual contribution of NR2B subunit of NMDA receptor and SK3 Ca2+-activated K+ channel to genetic predisposition to anorexia nervosa. J Psychiatr Res 2007; 41: 160-7
185. Mills IH, Park GR, Manara AR, et al. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM 1998; 91: 493-503
186. Hermanussen M, Tresguerres JA. A new anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Econ Hum Biol 2005; 3: 329-37
187. Brennan BP, Roberts JL, Fogarty KV, et al. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disord 2008; 41: 520-6
188. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1362-74
189. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008; 75: 218-65
190. Bisaga A, Aharonovich E, Cheng WY, et al. A placebocontrolled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010; 111: 97-104
191. Parsons CG, Danysz W, Zieglgansberger W. Excitatory amino acid neurotransmission. Handb Exp Pharmacol 2005; (169): 249-303
192. Nadler V, Kloog Y, Sokolovsky M. Distinctive structural requirement for the binding of uncompetitive blockers (phencyclidine-like drugs) to the NMDA receptor. Eur J Pharmacol 1990; 188: 97-104
193. MacDonald JF, Bartlett MC, Mody I, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 1991; 432: 483-508
194. Nevo I, Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995; 26: 305-36; discussion 337-42
195. Schummers J, Browning MD. Evidence for a role for GABAA and NMDA receptors in ethanol inhibition of long-term potentiation. Mol Brain Res 2001; 94: 9-14
196. Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007; 31: 604-11
197. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 2004; 172: 16-24
198. Krupitsky EM, Neznanova O, Masalov D, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 2007; 164: 519-23
199. Cornish JL, Duffy P, Kalivas PW. A role for nucleus accumbens glutamate transmission in the relapse to cocaineseeking behavior. Neuroscience 1999; 93: 1359-67
200. Hotsenpiller G, Giorgetti M, Wolf ME. Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure. Eur J Neurosci 2001; 14: 1843-55
201. Hayes RJ, Vorel SR, Spector J, et al. Electrical and chemical stimulation of the basolateral complex of the amygdala reinstates cocaine-seeking behavior in the rat. Psychopharmacology (Berl) 2003; 168: 75-83
202. Vorel SR, Liu X, Hayes RJ, et al. Relapse to cocaineseeking after hippocampal theta burst stimulation. Science 2001; 292: 1175-8
203. Kelamangalath L, Swant J, Stramiello M, et al. The effects of extinction training in reducing the reinstatement of drug-seeking behavior: involvement of NMDA receptors. Behav Brain Res 2007; 185: 119-28
204. Collins ED, Vosburg SK, Ward AS, et al. Memantine increases cardiovascular but not behavioral effects of cocaine in methadone-maintained humans. Pharmacol Biochem Behav 2006; 83: 47-55
205. Collins ED, Vosberg SK, Ward AS, et al. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Exp Clin Psychopharmacol 2007; 15: 228-37
206. Collins ED, Ward AS, McDowell DM, et al. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav Pharmacol 1998; 9: 587-98
207. Trujillo KA, Akil H. TheNMDAreceptor antagonist MK-801 increases morphine catalepsy and lethality. Pharmacol Biochem Behav 1991; 38: 673-5
208. Vandergriff J, Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawalinduced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 1999; 38: 217-22
209. Rasmussen K, Hsu MA, Vandergriff J. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphinewithdrawal-induced activation of locus coeruleus neurons. Neuropharmacology 2004; 46: 620-8
210. Rasmussen K, Vandergriff J. The selective iGluR1-4 (AMPA) antagonist LY300168 attenuates morphinewithdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. Neuropharmacology 2003; 44: 88-92
211. Tokuyama S, Zhu H, Oh S, et al. Further evidence for a role of NMDA receptors in the locus coeruleus in the expression of withdrawal syndrome from opioids. Neurochem Int 2001; 39: 103-9
212. Wang HL, Zhao Y, Xiang XH, et al. Blockade of ionotropic glutamatergic transmission in the ventral tegmental area attenuates the physical signs of morphine withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1079-87
213. Wang T, O'Connor WT, Ungerstedt U, et al. N-methyl-Daspartic acid biphasically regulates the biochemical and electrophysiological response of A10 dopamine neurons in the ventral tegmental area: in vivo microdialysis and in vitro electrophysiological studies. Brain Res 1994; 666: 255-62
214. Wang T, French ED. NMDA, kainate, and AMPA depolarize nondopamine neurons in the rat ventral tegmentum. Brain Res Bull 1995; 36: 39-43
215. Bisaga A, Comer SD, Ward AS, et al. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl) 2001; 157: 1-10
216. Krupitsky EM, Masalov DV, Burakov AM, et al. A pilot study of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts. Addictive Disorders & Their Treatment 2002; 1 (4): 143-6
217. Bisaga A, Sullivan MA, Cheng WY, et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend 2011; 119 (1-2): e23-9
218. Arias AJ, Feinn R, Covault J, et al. Memantine for alcohol dependence: an open-label pilot study. Addictive Disorders & Their Treatment 2007; 6 (2): 77-83
219. Evans SM, Levin FR, Brooks DJ, et al. A pilot doubleblind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 2007; 31: 775-82
220. Muhonen LH, Lonnqvist J, Lahti J, et al. Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence. Psychiatry Res 2009; 167: 115-22
221. Muhonen LH, Lahti J, Alho H, et al. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence. Psychiatry Res 2011; 186: 53-7
222. Thuerauf N, Lunkenheimer J, Lunkenheimer B, et al. Memantine fails to facilitate partial cigarette deprivation in smokers-no role of Memantine in the treatment of nicotine dependency? J Neural Transm 2007; 114: 351-7
223. Carlsson ML. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 2000; 102: 401-13
224. Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 5-26
225. Carrey NJ, MacMaster FP, Gaudet L, et al. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17: 11-7
226. Perlov E, Philipsen A, Hesslinger B, et al. Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder-a magnet resonance spectroscopy study. J Psychiatr Res 2007; 41: 934-41
227. Carrey N, MacMaster FP, Sparkes SJ, et al. Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series. J Child Adolesc Psychopharmacol 2002; 12: 331-6
228. Russell VA. Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder-the spontaneously hypertensive rat. Neurosci Biobehav Rev 2003; 27: 671-82
229. Warton FL, Howells FM, Russell VA. Increased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/ hyperactivity disorder-lack of effect of methylphenidate. Metab Brain Dis 2009; 24: 599-613
230. Jensen V, Rinholm JE, Johansen TJ, et al. N-methyl-Daspartate receptor subunit dysfunction at hippocampal glutamatergic synapses in an animal model of attentiondeficit/hyperactivity disorder. Neuroscience 2009; 158: 353-64
231. Lehohla M, Kellaway L, Russell VA. NMDA receptor function in the prefrontal cortex of a rat model for attention-deficit hyperactivity disorder. Metab Brain Dis 2004; 19: 35-42
232. Pozzi L, Baviera M, Sacchetti G, et al. Attention deficit induced by blockade of N-methyl D-aspartate receptors in the prefrontal cortex is associated with enhanced glutamate release and cAMP response element binding protein phosphorylation: role of metabotropic glutamate receptors 2/3. Neuroscience 2011; 176: 336-48
233. Turic D, Langley K, Mills S, et al. Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 2004; 9: 169-73
234. Dorval KM, Wigg KG, Crosbie J, et al. Association of the glutamate receptor subunit gene GRIN2B with attentiondeficit/hyperactivity disorder. Genes Brain Behav 2007; 6: 444-52
235. Adams J, Crosbie J, Wigg K, et al. Glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene as a positional candidate for attention-deficit/hyperactivity disorder in the 16p13 region. Mol Psychiatry 2004; 9: 494-9
236. Marusich JA, McCuddy WT, Beckmann JS, et al. Strain differences in self-administration of methylphenidate and sucrose pellets in a rat model of attention-deficit hyperactivity disorder. Behav Pharmacol 2011; 22: 794-804
237. Sukhanov IM, Zakharova ES, Danysz W, et al. Effects of NMDA receptor channel blockers, MK-801 and memantine, on locomotor activity and tolerance to delay of reward in Wistar-Kyoto and spontaneously hypertensive rats. Behav Pharmacol 2004; 15: 263-71
238. Findling RL, McNamara NK, Stansbrey RJ. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol 2007; 17: 19-33